공시 • Apr 11
Next Science Limited to Report Q1, 2025 Results on Apr 24, 2025 Next Science Limited announced that they will report Q1, 2025 results on Apr 24, 2025 공시 • Mar 11
Next Science Limited, Annual General Meeting, May 09, 2025 Next Science Limited, Annual General Meeting, May 09, 2025. 공시 • Feb 07
Next Science Limited to Report Fiscal Year 2024 Results on Feb 28, 2025 Next Science Limited announced that they will report fiscal year 2024 results on Feb 28, 2025 공시 • Jan 20
Next Science Limited to Report Q4, 2024 Results on Jan 23, 2025 Next Science Limited announced that they will report Q4, 2024 results on Jan 23, 2025 공시 • Jan 08
Next Science Limited and Next Science LLC Provide Update on Litigation Involving Former Employee Next Science Limited announced that a former employee, Michael Morello has filed a derivative complaint in the Duval County - Fourth Judicial Circuit Court in Florida, purportedly as a shareholder on behalf of the Company and its subsidiary, Next Science LLC, alleging breaches of fiduciary duties and mismanagement against several employees. Mr. Morello was VP, Wound Care Sales at Next Science LLC until December 2023. In May 2024, Next Science LLC commenced litigation against Mr. Morello and several former employees for breach of post-employment restraints. Mr. Morello's complaint makes several claims including that Next Science's XBIO technology has not been approved by the FDA as a biofilm eradication process and that the Company did not take adequate measures to address safety concerns about the use of its surgical solution XPERIENCETM in breast implant procedures. The Company confirms that the products it sells are safe, effective, approved by the FDA (the US healthcare regulatory authority) and promoted within their FDA approved intended use. The Board is concerned that the Complaint has not been brought in good faith due to the fact that Mr. Morello has sought to tie the derivative complaint to the Non-Compete Action. However, the Company is following recommended practice in undertaking an independent investigation into the matters alleged. Next Science has, in consultation with its insurers, engaged US attorneys in relation to both proceedings and the Company and Next Science LLC will continue to pursue the Non- Compete Action against Mr. Morello and several former employees for the breach of post- employment restraints. Next Science will provide further updates as and when there is material progress in these USA civil proceedings. 공시 • Oct 16
Next Science Limited to Report Q3, 2024 Results on Oct 22, 2024 Next Science Limited announced that they will report Q3, 2024 results on Oct 22, 2024 공시 • Jul 26
Next Science Limited to Report First Half, 2024 Results on Aug 30, 2024 Next Science Limited announced that they will report first half, 2024 results on Aug 30, 2024 공시 • Jul 10
Next Science Limited to Report Q2, 2024 Results on Jul 25, 2024 Next Science Limited announced that they will report Q2, 2024 results on Jul 25, 2024 공시 • Apr 23
Next Science Limited to Report Q1, 2024 Results on Apr 24, 2024 Next Science Limited announced that they will report Q1, 2024 results on Apr 24, 2024 공시 • Mar 04
Next Science Limited, Annual General Meeting, May 03, 2024 Next Science Limited, Annual General Meeting, May 03, 2024, at 10:01 E. Australia Standard Time. 공시 • Feb 16
Next Science Limited to Report Fiscal Year 2023 Results on Feb 28, 2024 Next Science Limited announced that they will report fiscal year 2023 results on Feb 28, 2024 공시 • Nov 01
Next Science Limited has completed a Follow-on Equity Offering in the amount of AUD 23.800122 million. Next Science Limited has completed a Follow-on Equity Offering in the amount of AUD 23.800122 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 28,571,429
Price\Range: AUD 0.42
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 25,851,024
Price\Range: AUD 0.42
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,244,504
Price\Range: AUD 0.42
Transaction Features: Reserved Share Offering; Subsequent Direct Listing 공시 • Oct 24
Next Science Limited Announces the Appointment of Katherine Ostin as Independent Non-Executive Director Next Science Limited announced the appointment of Ms. Katherine Ostin as an independent Non Executive Director of the Company and Chair of the Board’s Audit and Risk Committee with effect from 24 October 2023. Ms. Ostin is an experienced non-executive director and audit and risk committee chair. Ms. Ostin’s appointment strengthens the Board’s skills in a number of key areas including finance and accounting, audit, risk, governance, strategy and business development. Ms. Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has extensive experience in the aged care and healthcare sectors, having established and led KPMG’s New South Wales Health, Ageing and Human Services audit practice from 2006 to 2018. During her 24 years with KPMG, Ms. Ostin worked in Australia, the US, Asia, and the UK. Ms. Ostin currently serves as a Non-Executive Director of 3P Learning Limited, dusk Group Limited, Capral Limited and Alex Corporation Limited. She holds a Bachelor of Commerce (Accounting and Finance) from the University of New South Wales and is a Fellow of the Financial Services Institute of Australasia. Ms. Ostin is also a graduate of the Australian Institute of Company Directors (AICD). 공시 • Aug 23
Next Science Limited Announces Board Changes Next Science Limited announced the appointment of Ms. Aileen Stockburger as Chair of the Next Science Board of Directors and the appointment of a long standing advisor to the Company, Mr. Grant Hummel, as an independent Non-Executive Director, effective 23 August 2023, further strengthening the skills of the Board in a number of key areas including strategy, financial acumen, legal and governance. The timing of the Board changes has been brought about following the retirement of Mr. Mark Compton AM as Chair of the Company. Mr. Compton’s retirement from the Board follows two recent close family bereavements and his need to take some personal time. Aileen Stockburger has been an independent Non-Executive Director of the Company since 2018, having joined ahead of the Company’s admission to ASX. Ms Stockburger was most recently re-elected by shareholders at the Company’s 2023 Annual General Meeting. Prior to joining Next Science, Ms Stockburger was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group’s merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Ms Stockburger received her MBA and BS from The Wharton School, University of Pennsylvania and is a Certified Public Accountant (CPA USA). She is a Non-Executive Director of Microbot Medical and two private equity companies - Orchid Orthopaedic Solutions and Materna Medical. Ms Stockburger is also a graduate of the Australian Institute of Company Directors (AICD). Grant Hummel was part of the Company’s initial public offering (IPO) and ASX listing deal team in 2019. Mr. Hummel has been a partner of a major Australian law firm for over fifteen years. He has experience with corporate and commercial transactions, with particular expertise in advising primary care, allied health, medical device and life science clients. Mr. Hummel has been a non-executive director of GLG Corp. Ltd. since 2018 and serves as the Chair of GLG’s Nomination and Remuneration Committee and as a member of GLG’s Audit and Risk Committee. Mr. Hummel holds a Bachelor of Science with an honours degree in molecular genetics and a Bachelor of Laws (Honours) from the University of Tasmania. He also has a Graduate Diploma of Applied Finance and Investment from FINSIA (now Kaplan). Mr. Hummel has also been appointed as a member of the Board's Audit and Risk Committee and People, Culture and Remuneration Committee. Ms. Stockburger will remain as Chair of the Board's Audit and Risk Committee and independent Non-Executive Director, Mr. DanSpira, will continue to Chair the Board's People, Culture and Remuneration Committee. The Board will continue its ongoing search for at least one new independent non-executive director who may be US based. 공시 • Jun 29
Next Science Limited Commercialising Its Proprietary Xbiotm Suite of Products Next Science Limited announced commercialising its proprietary XBIOTM suite of products to reduce the impact of biofilm-based infections in human health, provide the following update. In advance of the forthcoming Appendix 4C and quarterly activity report, Next Science notes continuing improvement in the performance of the business across the quarter-to-date. Next Science advises, that with a few days left in the month, unaudited product sales for 2QFY23 are expected to be above USD 5.6 million. This compares with reported product sales of USD 4.4 million in 1QFY23. As the period for 1HFY23 is about to close, it is clear, that Next Science is on track to substantially exceed product sales in 1HFY22 (USD 5.2 million) and 2HFY22 (USD 6.1 million). This is due to the increased investment in sales and marketing that will continue during the establishment phase of the direct sales model for key products.